Mirum Pharmaceuticals, Inc.
NASDAQ:MIRM
40.8 (USD) • At close April 25, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 336.888 | 186.374 | 77.062 | 19.138 | 0 | 0 | 0 |
| Cost of Revenue
| 81.643 | 47.039 | 12.374 | 1.903 | 0.623 | 0.324 | 0 |
| Gross Profit
| 255.245 | 139.335 | 64.688 | 17.235 | -0.623 | -0.324 | 0 |
| Gross Profit Ratio
| 0.758 | 0.748 | 0.839 | 0.901 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 140.63 | 102.609 | 106.842 | 131.428 | 81.605 | 42.991 | 2.331 |
| General & Administrative Expenses
| 0 | 139.58 | 16.957 | 59.22 | 22.691 | 11.752 | 0.878 |
| Selling & Marketing Expenses
| 0 | 6.3 | 72.109 | 9.2 | 0 | 0 | -0.293 |
| SG&A
| 202.221 | 145.88 | 89.066 | 59.22 | 22.691 | 11.752 | 0.585 |
| Other Expenses
| 0 | 0 | 0.365 | 107.418 | -0.192 | -0.021 | 0 |
| Operating Expenses
| 342.851 | 248.489 | 195.908 | 190.648 | 104.296 | 54.743 | 2.916 |
| Operating Income
| -87.606 | -109.154 | -131.22 | -173.413 | -104.296 | -54.743 | -2.916 |
| Operating Income Ratio
| -0.26 | -0.586 | -1.703 | -9.061 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 0.694 | -53.27 | -10.851 | 89.462 | 1.032 | 2.211 | -14.432 |
| Income Before Tax
| -86.912 | -162.424 | -142.071 | -83.951 | -103.264 | -52.532 | -17.348 |
| Income Before Tax Ratio
| -0.258 | -0.871 | -1.844 | -4.387 | 0 | 0 | 0 |
| Income Tax Expense
| 1.03 | 0.991 | -6.406 | 0.037 | 0.006 | 0.021 | -4.374 |
| Net Income
| -87.942 | -163.415 | -135.665 | -83.988 | -103.27 | -52.553 | -17.348 |
| Net Income Ratio
| -0.261 | -0.877 | -1.76 | -4.389 | 0 | 0 | 0 |
| EPS
| -1.85 | -4 | -4.01 | -2.77 | -4.09 | -2.29 | -0.75 |
| EPS Diluted
| -1.85 | -4 | -4.01 | -2.77 | -4.09 | -2.29 | -0.75 |
| EBITDA
| -48.972 | -136.49 | -122.411 | -65.386 | -102.306 | -52.208 | -17.334 |
| EBITDA Ratio
| -0.145 | -0.732 | -1.588 | -3.417 | 0 | 0 | 0 |